Vanderbilt Center for Education/Research on Therapeutics

描述（由申请人提供）：范德比尔特治疗学教育和研究中心（CERT）被提议作为国家合作的一部分，系统地改进治疗学。我们的主题是促进医疗补助和退伍军人健康管理人群的最佳药物治疗。这些人群是我们关注的重点，因为他们易受次优治疗的影响，人口的过度代表性和高成本疾病是AHRQ和其他利益相关者联邦机构的优先事项，以及自动化数据库的可用性。CERT重点关注的弱势群体包括发育中的胎儿、幼儿、低收入母亲、非洲裔美国人和其他少数民族、有精神和身体残疾的人、慢性病患者、老年人和养老院的人。在这些人群中，我们将与我们的合作伙伴开展多学科研究和教育项目，这些项目将：

DESCRIPTION (Provided by the Applicant): The Vanderbilt Center for Education and Research on Therapeutics (CERT) is proposed as part of a national collaboration to systematically improve therapeutics. Our theme is Promoting Optimal Pharmacotherapy in Medicaid and Veterans' Health Administration Populations. These populations are our focus because of vulnerability to suboptimal therapeutics, over-representation of populations and high cost diseases that are priorities for AHRQ and other stakeholder federal agencies, and availability of automated databases. Vulnerable groups encompassed by the CERT focus include the developing fetus, young children, low-income mothers, African-Americans and other minorities, persons with mental and somatic disabilities, the chronically ill, the elderly, and persons in nursing homes. Within these populations, we will conduct multi-disciplinary research and education programs with our partners that will: 1. Fill critical gaps in the knowledge base through carefully selected studies of drug effects; 2. Optimize therapy by identifying suboptimal practices and conducting educational programs; 3. Evaluate potentially counterproductive policies. Our sub-theme is Reducing the Occurrence of Medication-Related Gastropathy, an important disease that is a priority for AHRQ and other federal agencies and with which we have substantial prior experience. The proposed new CERTs continues the work of an existing multi-disciplinary CERTs that has completed 63 projects and generated 50 publications to date, including 7 in The New England Journal of Medicine, 3 in Lancet, and 2 in JAMA. It has established strong partnerships with Tennessee Medicaid, the State Department of Health, the VA Tennessee Valley Healthcare System and Geriatric Research, Education and Clinical Center, the Food and Drug Administration, and the NIH. We propose 8 new projects. Four are of drug effects--1) SSRIs and birth defects, 2) ADHD drugs and adverse cardiovascular events, 3) Medications and sudden death, 4) Warfarin and antimicrobial interactions; three are educational programs-5) Improving use of therapy to prevent stroke/sepsis in children with sickle cell disease, 6) Improving gastroprotection in high-risk VA NSAID users; 7) Improving gastroprotection in high-risk Medicaid NSAID users; and one is a policy evaluation-8) Effect of Medicaid disenrollment for patients with serious mental illness. These projects are tightly linked to our theme/sub-theme and have the potential to materially improve clinical practice in highly vulnerable populations that often are under-represented in other research programs.